Is Zhejiang Xianju Pharmaceutical Co.,Ltd.'s (SZSE:002332) Recent Performance Tethered To Its Attractive Financial Prospects?

Simply Wall StNov 28 20:14 ET

gf sec: The upstream prices of penicillin and cephalosporins are fluctuating at a high level, while the active pharmaceutical ingredient is finding a bottom and stabilizing.

According to the data from the National Bureau of Statistics, in September 2024, the month-on-month PPI value of chemical drug active pharmaceutical ingredient manufacturing was 97.10, an increase of 2.0 compared to the previous month, and an increase of 1.63 from the average of 95.47 in the first half of 2024. Since the year 2023, when the month-on-month PPI of active pharmaceutical ingredient manufacturing fell below 100 for the whole year, the recent PPI value has been in an increasing state, indicating that the overall price of active pharmaceutical ingredients is in a phase of slight bottoming and recovery.

Zhitong FinanceNov 20 01:42 ET

We Think Zhejiang Xianju PharmaceuticalLtd (SZSE:002332) Can Stay On Top Of Its Debt

Simply Wall StNov 7 17:12 ET

Xianju Pharmaceutical: Report for the third quarter of 2024

SZSIOct 25 12:00 ET · Announcements

Zhejiang Xianju Pharmaceutical (002332.SZ): The net income for the first three quarters was 0.53 billion yuan, a year-on-year increase of 12.42%.

格隆汇October 25th, zhejiang xianju pharmaceutical (002332.SZ) announced its third quarter report for 2024, with the company achieving revenue of 3.237 billion yuan in the first three quarters, a decrease of 0.01% year-on-year; net income attributable to the shareholders of the listed company was 0.53 billion yuan, an increase of 12.42% year-on-year; net income attributable to the shareholders of the listed company after deducting non-recurring gains and losses was 0.521 billion yuan, an increase of 12.82% year-on-year; basic earnings per share were 0.5360 yuan.

Gelonghui FinanceOct 25 04:57 ET

GF Securities: The price of active pharmaceutical ingredients stabilizes at the bottom, with a slight increase in double bond prices.

In 2024, with relatively low inventory levels, some downstream formulation companies began to replenish their stockpiles. In addition, the continuous release of new active pharmaceutical ingredients after the expiration of patents, the sector is in a bottoming out stable recovery state.

Zhitong FinanceOct 16 05:03 ET